Pharmaceutical Industry
Filter News
Found 17,112 articles
-
Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.
-
BioSpace Movers & Shakers, Aug. 23
8/23/2019
Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments. -
In a head-to-head study, BeyondSpring’s plinabulin stood up to Amgen’s Neulasta (pegfilgrastim) in a quality of life study to prevent neutropenia, a common side effect for chemotherapy patients.
-
Eli Lilly won an arbitration hearing over accusations the Indianapolis-based company misused confidential information regarding the intellectual property of its former business partner, France-based Adocia S.A.
-
West Announces Participation in Upcoming September Investor Conferences
8/23/2019
West Pharmaceutical Services, Inc. announced that management will present an overview of the business at two investor conferences in September.
-
OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter formigenes
8/23/2019
OxThera AB announced that, based on a positive opinion from the Paediatric Committee, the EMA has agreed to the proposed PIP for Oxalobacter formigenes in the treatment of primary hyperoxaluria.
-
Cantargia and BioWa Extend Ongoing Collaboration around the POTELLIGENT® Technology
8/23/2019
Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of Cantargia’s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology.
-
CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting
8/23/2019
CStone Pharmaceuticals announced that the 22nd Annual Meeting of the Chinese Society of Clinical Oncology has accepted three abstracts on the clinical trials of CS1001, CS1002, and CS1003, the Company's three backbone immunotherapy candidates.
-
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study
8/23/2019
CStone Pharmaceuticals announced that the Company has recently received ethics approval from the Human Research Ethics Committee in Australia for the Phase I clinical trial of CS3002, and Australia's Therapeutic Goods Administration has acknowledged the electronic Clinical Trial Notification the Company submitted for the trial.
-
“This investment will further strengthen Pfizer’s leadership in gene therapy manufacturing technology,” stated Mike McDermott, president, Pfizer Global Supply.
-
Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan. The suit is an attempt to block Mylan from marketing a generic version of Novo Nordisk’s diabetes drug Victoza.
-
BioSpace Global Roundup, Aug. 22
8/22/2019
Companies from across the globe provide updates on their business and pipelines. -
ViiV Healthcare’s two-month injection proved to be as effective as monthly injections for HIV treatment that are currently on the market, the GlaxoSmithKline subsidiary said this morning as it continues to position itself for a leading share of the market alongside Gilead Sciences.
-
Shares of Retrophin have plunged more than 24% in premarket trading after the San Diego-based company announced its Phase III treatment for pantothenate kinase-associated neurodegeneration did not stack up against placebo.
-
Freeze and Thaw Systems Market Continues to Benefit from Biopharma Companies, Gains Remain Concentrated in ‘Disposable’ Systems
8/22/2019
A report on the freeze & thaw systems market which considers the global industry analysis 2014 – 2018 and forecast 2019-2029 projects that, the freeze & thaw systems market is expected to reach ~ US$ 270 Mn by the end of 2019 in terms of value, and is forecasted to reach ~ US$ 550 Bn by the end of 2029.
-
Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
8/22/2019
Retrophin, Inc. announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration did not meet its primary endpoint and did not demonstrate a difference between treatment groups.
-
Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity
8/22/2019
Biocon Ltd, Asia’s premier biopharmaceuticals company, Biocon Ltd announced that it’s subsidiary in Malaysia, Biocon Sdn.
-
Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019
8/22/2019
Vivoryon Therapeutics AG, will publish its Half Year Results for 2019 on Thursday, August 29, 2019.
-
Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer
8/22/2019
Merck announced new data from the company’s leading clinical development program in lung cancer will be presented at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain from Sept. 7-10, 2019.
-
Sobi has Entered Into Agreement to Sell Priority Review Voucher
8/22/2019
Swedish Orphan Biovitrum AB has entered into an agreement to sell a US Food and Drug Administration Priority Review Voucher to AstraZeneca for a total cash consideration of USD 95 M.